Sanofi SA
79.58
15-September-25 08:05:52
15 minutes delayed
Stocks
-1.13
-1.39%
Today's range
79.57 - 81.35
ISIN
FR0000120578
Source
Cboe
-
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
23 Apr 2025 22:30:00 By Nasdaq GlobeNewswire
-
18 Apr 2025 08:15:00 By Nasdaq GlobeNewswire
-
14 Apr 2025 22:00:00 By Nasdaq GlobeNewswire
-
08 Apr 2025 10:11:02 By Nasdaq GlobeNewswire
-
Sanofi: Information concerning the total number of voting rights and shares - February 2025
03 Apr 2025 11:08:15 By Nasdaq GlobeNewswire
-
02 Apr 2025 22:00:00 By Nasdaq GlobeNewswire
-
28 Mar 2025 13:07:34 By Nasdaq GlobeNewswire
-
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
27 Mar 2025 23:00:00 By Nasdaq GlobeNewswire
-
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
25 Mar 2025 23:00:00 By Nasdaq GlobeNewswire
-
24 Mar 2025 23:00:00 By Nasdaq GlobeNewswire
-
Press Release: Availability of the Q1 2025 Aide mémoire
23 Mar 2025 23:30:00 By Nasdaq GlobeNewswire
-
19 Mar 2025 23:00:00 By Nasdaq GlobeNewswire
-
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
08 Mar 2025 10:00:00 By Nasdaq GlobeNewswire
-
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
05 Mar 2025 09:10:00 By Nasdaq GlobeNewswire
-
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
24 Feb 2025 22:00:00 By Nasdaq GlobeNewswire
-
21 Feb 2025 23:30:00 By Nasdaq GlobeNewswire
-
Press Release: Sanofi and CD&R sign Opella share purchase agreement
18 Feb 2025 22:30:00 By Nasdaq GlobeNewswire
-
17 Feb 2025 22:00:00 By Nasdaq GlobeNewswire
-
13 Feb 2025 11:08:49 By Nasdaq GlobeNewswire
-
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
12 Feb 2025 22:00:00 By Nasdaq GlobeNewswire